Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK6 | P43250 | 11/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5202870 | 0.87 | NPC1 (0.58) | GRK6MAPTCHEK1CHEK2PDGFRB | |
| SCHEMBL14409210 | 0.80 | PDGFRB (0.47) | MAPTCHEK1CHEK2PDGFRBPDGFRA | |
| SCHEMBL6028508 | 0.77 | FFAR1 (0.48) | MAPTCHEK1CHEK2PDGFRBPDGFRA | |
| SCHEMBL6652114 | 0.77 | CHEK1 (0.47) | MAPTCHEK1CHEK2PDGFRBPDGFRA | |
| SCHEMBL5832416 | 0.76 | PDGFRB (0.55) | CHEK1CHEK2PDGFRBPDGFRAALDH1A1 | |
| SCHEMBL5832414 | 0.75 | PDGFRB (0.54) | CHEK1CHEK2PDGFRBPDGFRAALDH1A1 | |
| SCHEMBL342810 | 0.75 | ALDH1A1 (0.53) | MAPTALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL4039887 | 0.75 | L3MBTL1 (0.56) | GRK6MAPTALDH1A1KDM4EGAA | |
| SCHEMBL11046284 | 0.73 | PDE4A (0.57) | MAPTCHEK1CHEK2PDGFRBPDGFRA | |
| SCHEMBL7161673 | 0.72 | CHEK1 (0.48) | MAPTCHEK1CHEK2PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167105-A1 | CCR-3 receptor antagonists | DU BOIS DAISY J | 2006-07-27 | — | — | US | disclosed |
| US-7049317-B2 | CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-05-23 | — | — | US | disclosed |
| US-6984643-B2 | 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2006-01-10 | — | — | US | disclosed |
| EP-1521582-A1 | 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-04-13 | — | — | EP | disclosed |
| EP-1427696-A1 | CCR-3 RECEPTOR ANTAGONISTS V | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-16 | — | — | EP | disclosed |
| US-20040014775-A1 | 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists | ROCHE PALO ALTO LLC | 2004-01-22 | — | — | US | disclosed |
| WO-2004004731-A1 | 2, 5-SUBSTITUTED PYRIMIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS IX | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-15 | — | — | WO | disclosed |
| US-20030119885-A1 | CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-06-26 | — | — | US | disclosed |
| WO-2003022799-A1 | CCR-3 RECEPTOR ANTAGONISTS V | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014775-A1 | 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCRL2 | GRK6 275/4885MAPT 4134/4885ATM 1991/4885 |
| US-20030119885-A1 | CCR-3 receptor antagonists | CCR1, CCR3, CCR4 | GRK6 270/4885MAPT 4357/4885ATM 2459/4885 |
| US-20060167105-A1 | CCR-3 receptor antagonists | CCR3, CCR1, CCR4 | GRK6 342/4885MAPT 4308/4885ATM 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.